<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta name="description" content="The Investor Relations website contains information about Intellia Therapeutics&#039;s business for stockholders, potential investors, and financial analysts." />
<meta property="og:site_name" content="Intellia Therapeutics" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://ir.intelliatx.com/press-releases" />
<meta property="og:title" content="Press Releases - Intellia Therapeutics" />
<meta property="og:description" content="The Investor Relations website contains information about Intellia Therapeutics&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb88161/files/favicon_0.png" type="image/png" />
<link rel="alternate" hreflang="en" href="https://ir.intelliatx.com/press-releases" />
<link rel="canonical" href="https://ir.intelliatx.com/press-releases" />
<link rel="shortlink" href="https://ir.intelliatx.com/node/5816" />

    <title>Press Releases - Intellia Therapeutics</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb88161/files/css/css_QDPDNY5dYzS6v7Ovi4UbDhMKdQksLoUfzw4IOzHCP4I.css?delta=0&amp;language=en&amp;theme=client_site_202&amp;include=eJyVjEsOAjEMQy9UUTQXitxONBTaBCXhd3s67JDYsLOfni3NaMAuHLQiQKVrveTBEDKuOgbL5E2F6gkWSX76EPSXB9lUZaMC-0N3CpTOqapxXu12RT_gjOcXWBu6bsnnjEcucP587yHvoVUVT7U3liBvwbQcl6x3tofN5m_9bls4" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb88161/files/css/css_gChMw9VUk6HxXIyLC6AcHymJce6djOuxJHCsvKR-vMM.css?delta=1&amp;language=en&amp;theme=client_site_202&amp;include=eJyVjEsOAjEMQy9UUTQXitxONBTaBCXhd3s67JDYsLOfni3NaMAuHLQiQKVrveTBEDKuOgbL5E2F6gkWSX76EPSXB9lUZaMC-0N3CpTOqapxXu12RT_gjOcXWBu6bsnnjEcucP587yHvoVUVT7U3liBvwbQcl6x3tofN5m_9bls4" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7" data-cookieconsent="ignore"></script>
<script src="/sites/g/files/knoqqb88161/files/js/js_AeIzmGI4i4LVY9Oi04QLDdFsQbfZKEMqZ_KF770ZrT4.js?scope=header&amp;delta=1&amp;language=en&amp;theme=client_site_202&amp;include=eJxtjYEKwlAIRX9o7MV-SJzPDZvbC3Wt_r63VVQQgtwr514XMaCJs0QxyBh1emVPH9ksFZlXDZkrhunXNqTCS4BLMHSnLpUr22bVvYJoE8fRDL0WmtLfazuIBttQbD5im-SRw9OXbpGI3aUXlbjDjtZF6_PPBUdOb9HiGW-AOQMpugMqW_gD7fBdMg" data-cookieconsent="ignore"></script>

    <script id="Cookiebot" src="https://consent.cookiebot.com/uc.js" data-cbid="6cca6ff4-7a38-490b-abcf-1e954edc4b1a" data-blockingmode="auto" type="text/javascript"></script>
<script data-cookieconsent="ignore">
    window.dataLayer = window.dataLayer || [];
    function gtag() {
        dataLayer.push(arguments);
    }
    gtag("consent", "default", {
        ad_personalization: "denied",
        ad_storage: "denied",
        ad_user_data: "denied",
        analytics_storage: "denied",
        functionality_storage: "denied",
        personalization_storage: "denied",
        security_storage: "granted",
        wait_for_update: 500,
    });
    gtag("set", "ads_data_redaction", true);
    gtag("set", "url_passthrough", false);
</script>
<script>
function CookiebotCallback_OnAccept() {
  Cookiebot.changed && document.location.reload();
}
</script>


<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-T87SBDCFS6"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());


  gtag('config', 'G-T87SBDCFS6');
</script>

<script src="https://cdn.userway.org/widget.js" data-account="Q87J9yY0vo"></script>
  </head>
  <body class="nir-node nir-node--type-nir-landing-page nir-node--5816 reborn_lite path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    
<div class="wrapper">
    <div class="header-holder">
        <header class="header">
            <div class="container">
                <div class="logo">
                    <a href="https://www.intelliatx.com/" aria-label="Go to Intellia Therapeutics home page"><img src="/sites/g/files/knoqqb88161/themes/site/client_site_202/dist/images/logo.svg" alt="Intellia Therapeutics home page" /></a>
                </div>
                <div class="drop-nav">
                                        <nav class="main-nav">
                        

                        
        

                              <ul class="main-menu">
                          <li class="menu-item">
          <a href="https://www.intelliatx.com/">Home</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/about/" class="opener">About</a>
                                    <ul class="sub-menu">
                          <li class="menu-item">
          <a href="https://www.intelliatx.com/about/">Who We Are</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/about/#core-values-anchor">Core Values</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/about/#leadership-anchor">Leadership</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/about/#partners-anchor">Partners</a>
                  </li>
          </ul>
  
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/our-science/" class="opener">Our Science</a>
                                    <ul class="sub-menu">
                          <li class="menu-item">
          <a href="https://www.intelliatx.com/our-science/">What is CRISPR?</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/our-science/?sid=crispr-videos">CRISPR Videos</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/our-science/full-spectrum-approach/">Full-Spectrum Approach</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/our-science/publications-and-presentations/">Scientific Publications &amp; Presentations</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/our-science/glossary/">Glossary</a>
                  </li>
          </ul>
  
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/pipeline/" class="opener">Programs &amp; Pipeline</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/patient-stories/" class="opener">Patient Focus</a>
                                    <ul class="sub-menu">
                          <li class="menu-item">
          <a href="https://www.intelliatx.com/disease-focus/">Disease Focus</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/patient-stories/">Patient Stories</a>
                  </li>
          </ul>
  
                  </li>
                      <li class="current_page_ancestor menu-item">
          <a href="/" class="opener" data-drupal-link-system-path="&lt;front&gt;">Investors &amp; Media</a>
                                    <ul class="sub-menu">
                          <li class="menu-item">
          <a href="/" data-drupal-link-system-path="&lt;front&gt;">Overview</a>
                  </li>
                      <li class="current_page_item menu-item">
          <a href="/press-releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/our-science/publications-and-presentations/">Scientific Publications &amp; Presentations</a>
                  </li>
                      <li class="menu-item">
          <a href="/static-files/a57908a6-aaca-404d-9072-32471cd3d41e" data-drupal-link-system-path="static-files/a57908a6-aaca-404d-9072-32471cd3d41e">Corporate Presentation</a>
                  </li>
                      <li class="menu-item">
          <a href="/static-files/10e6a1dc-d626-44ad-b184-fe0e149189e7" data-drupal-link-system-path="static-files/10e6a1dc-d626-44ad-b184-fe0e149189e7">Corporate Responsibility Report</a>
                  </li>
                      <li class="menu-item">
          <a href="/events-and-presentations/upcoming-events" data-drupal-link-system-path="node/5826">Events &amp; Presentations</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/press-kit/">Press Kit</a>
                  </li>
                      <li class="menu-item">
          <a href="/corporate-governance/documents-charters" data-drupal-link-system-path="node/7031">Corporate Governance</a>
                  </li>
                      <li class="menu-item">
          <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">Financial Info</a>
                  </li>
                      <li class="menu-item">
          <a href="/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                  </li>
                      <li class="menu-item">
          <a href="/investor-resources/investor-faqs" data-drupal-link-system-path="node/5941">Investor Resources</a>
                  </li>
          </ul>
  
                  </li>
          </ul>
  


    

                        
        

                              <ul class="main-menu">
                          <li class="menu-item">
          <a href="https://www.intelliatx.com/careers/" class="opener">Careers</a>
                                    <ul class="sub-menu">
                          <li class="menu-item">
          <a href="https://www.intelliatx.com/careers/">Life @ Intellia</a>
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/careers/join-us/">Join Us</a>
                  </li>
          </ul>
  
                  </li>
                      <li class="menu-item">
          <a href="https://www.intelliatx.com/contact/">Contact</a>
                  </li>
          </ul>
  


    
                    </nav>
                                                                

                        
        

                              <ul class="social-networks">
                                            <li>
          <a href="https://twitter.com/intelliatx" target="_blank" rel="noopener" class="twitter" aria-label="Twitter">            <svg xmlns="http://www.w3.org/2000/svg" width="22" height="22" viewBox="0 0 512 512"><path fill="#fff" d="M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z"/></svg>
          </a>
                  </li>
                                        <li>
          <a href="https://www.instagram.com/intelliatx/" target="_blank" rel="noopener" class="instagram" aria-label="Instagram">            <svg xmlns="http://www.w3.org/2000/svg" width="22" height="22" viewBox="0 0 448 512"><path fill="#fff" d="M224.1 141c-63.6 0-114.9 51.3-114.9 114.9s51.3 114.9 114.9 114.9S339 319.5 339 255.9 287.7 141 224.1 141zm0 189.6c-41.1 0-74.7-33.5-74.7-74.7s33.5-74.7 74.7-74.7 74.7 33.5 74.7 74.7-33.6 74.7-74.7 74.7zm146.4-194.3c0 14.9-12 26.8-26.8 26.8-14.9 0-26.8-12-26.8-26.8s12-26.8 26.8-26.8 26.8 12 26.8 26.8zm76.1 27.2c-1.7-35.9-9.9-67.7-36.2-93.9-26.2-26.2-58-34.4-93.9-36.2-37-2.1-147.9-2.1-184.9 0-35.8 1.7-67.6 9.9-93.9 36.1s-34.4 58-36.2 93.9c-2.1 37-2.1 147.9 0 184.9 1.7 35.9 9.9 67.7 36.2 93.9s58 34.4 93.9 36.2c37 2.1 147.9 2.1 184.9 0 35.9-1.7 67.7-9.9 93.9-36.2 26.2-26.2 34.4-58 36.2-93.9 2.1-37 2.1-147.8 0-184.8zM398.8 388c-7.8 19.6-22.9 34.7-42.6 42.6-29.5 11.7-99.5 9-132.1 9s-102.7 2.6-132.1-9c-19.6-7.8-34.7-22.9-42.6-42.6-11.7-29.5-9-99.5-9-132.1s-2.6-102.7 9-132.1c7.8-19.6 22.9-34.7 42.6-42.6 29.5-11.7 99.5-9 132.1-9s102.7-2.6 132.1 9c19.6 7.8 34.7 22.9 42.6 42.6 11.7 29.5 9 99.5 9 132.1s2.7 102.7-9 132.1z"/></svg>
          </a>
                  </li>
                                        <li>
          <a href="https://www.linkedin.com/company/intellia-therapeutics-inc-/" target="_blank" rel="noopener" class="linkedin" aria-label="Linkedin">            <svg xmlns="http://www.w3.org/2000/svg" width="22" height="22" viewBox="0 0 448 512"><path fill="#fff" d="M100.28 448H7.4V148.9h92.88zM53.79 108.1C24.09 108.1 0 83.5 0 53.8a53.79 53.79 0 0 1 107.58 0c0 29.7-24.1 54.3-53.79 54.3zM447.9 448h-92.68V302.4c0-34.7-.7-79.2-48.29-79.2-48.29 0-55.69 37.7-55.69 76.7V448h-92.78V148.9h89.08v40.8h1.3c12.4-23.5 42.69-48.3 87.88-48.3 94 0 111.28 61.9 111.28 142.3V448z"/></svg>
          </a>
                  </li>
          </ul>
  


    
                                    </div>
                <a href="#" class="nav-opener">menu</a>
            </div>
        </header>
    </div>
    <div class="page-holder">
        <main class="main" id="main">
            <section class="hero-section subpage">
                                                                                    <img class="background" src="/sites/g/files/knoqqb88161/themes/site/client_site_202/dist/images/masthead_investors_press-release.jpg" alt="Intellia Therapeutics Head office building" />
                <div class="container">
                    <div class="text-area">
                                                                                                                            <h1>Press Releases</h1>
                                            </div>
                </div>
            </section>
            <section class="sub-nav-section">
                <div class="container">
                	      					

                        
    <h2 class="visually-hidden" id="block-client-site-202-investorrelations-3-menu">investor relations</h2>
    

                              <ul class="sub-nav">
                          <li>
          <a href="/investor-overview" title="investor relations" data-drupal-link-system-path="node/5806">Overview</a>
                  </li>
                      <li class="current_page_item">
          <a href="/press-releases" target="" rel="" title="press releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                  </li>
                      <li>
          <a href="https://www.intelliatx.com/our-science/publications-and-presentations/">Scientific Publications &amp; Presentations</a>
                  </li>
                      <li>
          <a href="/static-files/a57908a6-aaca-404d-9072-32471cd3d41e" target="_blank" data-drupal-link-system-path="static-files/a57908a6-aaca-404d-9072-32471cd3d41e">Corporate Presentation</a>
                  </li>
                      <li>
          <a href="/static-files/10e6a1dc-d626-44ad-b184-fe0e149189e7" data-drupal-link-system-path="static-files/10e6a1dc-d626-44ad-b184-fe0e149189e7">Corporate Responsibility Report</a>
                  </li>
                      <li>
          <a href="/events-and-presentations/upcoming-events" target="" rel="" title="events &amp; presentations" data-drupal-link-system-path="node/5826">Events &amp; Presentations</a>
                  </li>
                      <li>
          <a href="https://www.intelliatx.com/press-kit/">Press Kit</a>
                  </li>
                      <li>
          <a href="/corporate-governance/documents-charters" target="" rel="" title="corporate governance" data-drupal-link-system-path="node/7031">Corporate Governance</a>
                  </li>
                      <li>
          <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">Financial Info</a>
                  </li>
                      <li>
          <a href="/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                  </li>
                      <li>
          <a href="/investor-resources/investor-faqs" data-drupal-link-system-path="node/5941">Investor Resources</a>
                  </li>
          </ul>
  


    
      				                </div>
            </section>
            <section class="base-section ">
                                <div class="container">
                	                                        
                    <div >
                        	                    <div  class="lf-5816 cl-md-12" id="lfg-content">
	                          <div class="region region-content">
    <div data-drupal-messages-fallback class="hidden"></div>

<div id="block-client-site-202-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--bcfd05ae-95bf-40a1-bd93-465985ff8bed block--bcfd05ae-95bf-40a1-bd93-465985ff8bed--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
    <div>
    
<div  class="panel-display boxton clearfix">

  <div class="container-fluid">
    <div class="row">
      <div class="col-md-12 radix-layouts-content panel-panel">
        <div  class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--nir-news__widget block--nir-news__widget--5816 block--contentmain--nir-news__widget block--contentmain--nir-news__widget--5816 block--e970fcb0-c51d-4b24-87d5-d13c384b86f6 block--e970fcb0-c51d-4b24-87d5-d13c384b86f6--5816 block block-nir-news block-nir-news__widget">
  
    
      <div class="nir-widget llf-container-fluid-full">
    <div class="llf-row llf-no-gutters">
        <div class="llf-col-12">
                        <div class="nir-widget--content">
                                  <div class="nir-widget--form">
                    <form class="nir-widget-form-base" data-drupal-selector="widget-form-base" action="/press-releases?page=6" method="get" id="widget-form-base" accept-charset="UTF-8">
  <div class="nir-widgets--field-container nir-widgets--field-container--yeartimezone js-form-wrapper form-wrapper" data-drupal-selector="edit-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-year" id="edit-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-year"><div class="two-col-field form-item js-form-item js-form-type-select form-type-select form-item-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-year-value js-form-item-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-year-value">
      <label for="edit-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-year-value">Year</label>
        <select data-drupal-selector="edit-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-year-value" id="edit-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-year-value" name="f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf_year[value]" class="form-select"><option value="_none">All</option><option value="2025">2025</option><option value="2024">2024</option><option value="2023">2023</option><option value="2022">2022</option><option value="2021">2021</option><option value="2020">2020</option><option value="2019">2019</option><option value="2018">2018</option><option value="2017">2017</option><option value="2016">2016</option><option value="2015">2015</option><option value="2014">2014</option></select>
        </div>
</div>
<input data-drupal-selector="edit-submit" type="submit" id="edit-submit" name="op" value="Filter" class="button button--primary js-form-submit form-submit" />
<input data-drupal-selector="edit-f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf-widget-id" type="hidden" name="f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf_widget_id" value="f1e9ca5ea896b78a6a52d59aa2236a47c174abbf6051bfacbec7ac1c318145cf" />
<input data-drupal-selector="form-pdqr4rnokobnzxufu92kutf5utomnwlucqj57-4cjf0" type="hidden" name="form_build_id" value="form-pDqr4rnOKOBNzXufU92KuTF5utomnWlucQj57_4Cjf0" />
<input data-drupal-selector="edit-widget-form-base" type="hidden" name="form_id" value="widget_form_base" />

</form>

                  </div>
                                <div class="nir-widget--list  llf-mb-3">
                                      <div class="press-row">
                        
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics Announces Pricing of Public Offering of Common Stock">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Nov 30, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics Announces Pricing of Public Offering of Common Stock</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          CAMBRIDGE, Mass. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies,&nbsp;announced today the pricing of an underwritten public offering
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-announces-pricing-public-offering-common-3" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics Announces Proposed Public Offering of Common Stock">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Nov 30, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics Announces Proposed Public Offering of Common Stock</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          CAMBRIDGE, Mass. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-announces-proposed-public-offering-3" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma &amp; Immunology 2022 Annual Scientific Meeting">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Nov 12, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma &amp; Immunology 2022 Annual Scientific Meeting</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-presents-new-interim-data-first-human" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Nov 05, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-presents-updated-interim-data-cardiomyopathy-arm" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Nov 03, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and sustained mean serum TTR reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28; additional data to be presented in late-breaking, oral presentation at AHA on November 5
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-announces-third-quarter-2022-financial" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics to Present Updated Interim Clinical Data from  Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of  Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Oct 31, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics to Present Updated Interim Clinical Data from  Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of  Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          - New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohorts CAMBRIDGE, Mass. , Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-present-updated-interim-clinical-data-0" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Oct 27, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          CAMBRIDGE, Mass. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its third quarter 2022 financial results and
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-hold-conference-call-discuss-third-4" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics to Present at October Healthcare Investor Conferences">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Sep 26, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics to Present at October Healthcare Investor Conferences</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          CAMBRIDGE, Mass. , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-present-october-healthcare-investor-2" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Sep 16, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-and-regeneron-announce-initial-data-cardiomyopathy-arm" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
    

<div class="col">
  <div class="press-card">
    <article class="clearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted nir-widget-article llf-p-0" data-title="Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)">
      <div class="llf-container-fluid-full">
        <div class="llf-row llf-no-gutters llf-flex-sm-nowrap">

        
          <div class="llf-col-md-12 llf-px-0 lfg-details px-0">

                      <time class="date" data-label="Date">Sep 16, 2022</time>
          
            <div class="nir-widget--field" data-label="Title">

                              <div class="nir-widget--field nir-widget--news--headline">
                                                                    <p>Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)</p>
                                                          </div>
              
                                                    <div class="nir-widget--field nir-widget--news--teaser" data-label="Teaser">
                          Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively,
                      </div>
                              
                                <a href="/news-releases/news-release-details/intellia-therapeutics-announces-positive-interim-clinical-data" class="read-more llf-text-uppercase">Read More</a>
              
            </div>

          
          
          


          
          </div>
        </div>
      </div>
    </article>
  </div>
</div>
                    </div>
                                  </div>
            </div>
        </div>
    </div>
      <div class="llf-row llf-no-gutters lfg-widget-footer llf-align-items-center llf-justify-content-center">
        <div class="llf-col-lg-9">
            <div class="nir-widget--pager">
              



  <nav class="pager" role="navigation" aria-labelledby="pagination-heading--3">
      <strong id="pagination-heading--3" class="visually-hidden">Pagination</strong>
    <ul class="pager__items js-pager__items">
                    <li class="pager__item pager__item--first">
          <a href="?page=0" title="Go to first page">
            <span class="visually-hidden">First page</span>
            <span aria-hidden="true">«</span>
          </a>
        </li>
                          <li class="pager__item pager__item--previous">
          <a href="?page=5" title="Go to previous page" rel="prev">
            <span class="visually-hidden">Previous page</span>
            <span aria-hidden="true">‹</span>
          </a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation"><span>&hellip;</span></li>
      
                          <li class="pager__item">
                                          <a href="?page=4" title="Go to page 5">
            <span class="visually-hidden">
              Page
            </span>5</a>
        </li>
                  <li class="pager__item">
                                          <a href="?page=5" title="Go to page 6">
            <span class="visually-hidden">
              Page
            </span>6</a>
        </li>
                  <li class="pager__item is-active">
                                          <a href="?page=6" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>7</a>
        </li>
                  <li class="pager__item">
                                          <a href="?page=7" title="Go to page 8">
            <span class="visually-hidden">
              Page
            </span>8</a>
        </li>
                  <li class="pager__item">
                                          <a href="?page=8" title="Go to page 9">
            <span class="visually-hidden">
              Page
            </span>9</a>
        </li>
          

                    <li class="pager__item pager__item--ellipsis" role="presentation"><span>&hellip;</span></li>
                          <li class="pager__item pager__item--next">
          <a href="?page=7" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">›</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?page=25" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true"> »</span>
          </a>
        </li>
          </ul>
  </nav>

            </div>
        </div>
        <div class="llf-col-lg-3">
            <div class="nir-widget--total-results">
              
            </div>
        </div>
    </div>
  </div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

	                    </div>
                    </div>
                </div>
            </section>
            
            
            
        	
                        <section class="base-section grey-bg-color quick-section">
                <div class="container">
					

            
    <div class="head-box grey-bg-decor">
        <h2 id="block-quicklinks-menu">Quick<br />Links</h2>
    </div>
    

                              <div class="quick-row">
                  <div class="col">
                    <a href="/rss-feeds" class="rss-feeds quick-link" data-drupal-link-system-path="node/5951">            <span class="icon">
                              <svg xmlns="http://www.w3.org/2000/svg" width="41" height="42" viewBox="0 0 41 42">
                  <g>
                    <g>
                      <path fill="#fff" d="M6.564 34.843c-.85-.849-1.274-1.885-1.274-3.106 0-1.222.425-2.258 1.274-3.107.849-.849 1.885-1.274 3.107-1.274 1.22 0 2.257.425 3.106 1.274.849.85 1.274 1.885 1.274 3.107 0 1.221-.425 2.257-1.274 3.106-.85.85-1.885 1.274-3.106 1.274-1.222 0-2.258-.425-3.107-1.274zm25.098 1.274c0-3.635-.693-7.055-2.078-10.258-1.386-3.204-3.271-5.997-5.655-8.38-2.384-2.385-5.177-4.27-8.381-5.655-3.203-1.386-6.622-2.079-10.258-2.079V5.722c4.202 0 8.143.797 11.823 2.392 3.68 1.594 6.898 3.77 9.655 6.526 2.756 2.756 4.93 5.974 6.526 9.654 1.594 3.68 2.39 7.621 2.39 11.823zm-10.638 0c0-4.708-1.445-8.567-4.336-11.577-2.89-3.009-6.69-4.514-11.398-4.514v-4.023c2.89 0 5.543.506 7.957 1.52 2.413 1.013 4.492 2.413 6.235 4.201 1.743 1.788 3.106 3.911 4.09 6.37.983 2.458 1.475 5.133 1.475 8.023z"/>
                    </g>
                    <g>
                      <path fill="none" stroke="#fff" stroke-miterlimit="20" stroke-width=".9" d="M6.564 34.843c-.85-.849-1.274-1.885-1.274-3.106 0-1.222.425-2.258 1.274-3.107.849-.849 1.885-1.274 3.107-1.274 1.22 0 2.257.425 3.106 1.274.849.85 1.274 1.885 1.274 3.107 0 1.221-.425 2.257-1.274 3.106-.85.85-1.885 1.274-3.106 1.274-1.222 0-2.258-.425-3.107-1.274zm23.02-8.984c-1.386-3.204-3.271-5.997-5.655-8.38-2.384-2.385-5.177-4.27-8.381-5.655-3.203-1.386-6.622-2.079-10.258-2.079V5.722c4.202 0 8.143.797 11.823 2.392 3.68 1.594 6.898 3.77 9.655 6.526 2.756 2.756 4.93 5.974 6.526 9.654 1.594 3.68 2.39 7.621 2.39 11.823h-4.022c0-3.635-.693-7.055-2.078-10.258zM16.688 24.54c-2.89-3.009-6.69-4.514-11.398-4.514v-4.023c2.89 0 5.543.506 7.957 1.52 2.413 1.013 4.492 2.413 6.235 4.201 1.743 1.788 3.106 3.911 4.09 6.37.983 2.458 1.475 5.133 1.475 8.023h-4.023c0-4.708-1.445-8.567-4.336-11.577z"/>
                    </g>
                  </g>
                </svg>
                          </span>
            <div class="wrap">
              <span class="txt">RSS FEEDS</span>
              <span class="arrow">
                <svg xmlns="http://www.w3.org/2000/svg" width="29" height="15" viewBox="0 0 29 15">
                  <g>
                    <g><path fill="#d75332" d="M7 7.492h15.844" /></g>
                    <g><path fill="none" stroke="#d75332" stroke-miterlimit="20" stroke-width="1.4" d="M7 7.492h14.325" /></g>
                    <g><path fill="#d75332" d="M16.686 13.218l-.955-1.025 5.057-4.7-5.057-4.7.955-1.025 6.157 5.725z" /></g>
                  </g>
                </svg>
              </span>
            </div>
          </a>
                  </div>
              <div class="col">
                    <a href="/investor-resources/email-alerts" class="email-alerts quick-link" data-drupal-link-system-path="node/5946">            <span class="icon">
                              <svg xmlns="http://www.w3.org/2000/svg" width="45" height="44" viewBox="0 0 45 44">
                  <g>
                    <g>
                      <path fill="#fff" d="M30.923 24.06h-5.84a6.172 6.172 0 0 1-2.23 2.576c-.975.636-2.07.953-3.287.953s-2.319-.317-3.306-.953a5.852 5.852 0 0 1-2.21-2.576H8.21v6.612h22.713zm-7.625-2.433h7.625V7.958H8.21v13.67h7.624c0 .97.365 1.8 1.096 2.491.731.691 1.61 1.037 2.637 1.037 1.026 0 1.905-.346 2.636-1.037.73-.69 1.096-1.522 1.096-2.492zM8.21 33.107c-.649 0-1.217-.245-1.704-.73-.486-.488-.73-1.056-.73-1.705V7.958c0-.649.244-1.217.73-1.704.487-.487 1.055-.73 1.704-.73h22.714c.65 0 1.217.243 1.704.73.487.487.73 1.055.73 1.704v22.714c0 .65-.243 1.217-.73 1.704-.487.486-1.055.73-1.704.73zm3.425 5.858v-2.434h25.148V11.383h2.434v25.148c0 .65-.243 1.217-.73 1.703-.487.487-1.055.731-1.704.731zM8.21 30.672h22.714" />
                    </g>
                    <g>
                      <path fill="none" stroke="#fff" stroke-miterlimit="20" stroke-width=".87" d="M25.083 24.06a6.172 6.172 0 0 1-2.23 2.576c-.975.636-2.07.953-3.287.953s-2.319-.317-3.306-.953a5.852 5.852 0 0 1-2.21-2.576H8.21v6.612h22.713V24.06zm-1.785-2.433h7.625V7.958H8.21v13.67h7.624c0 .97.365 1.8 1.096 2.491.731.691 1.61 1.037 2.637 1.037 1.026 0 1.905-.346 2.636-1.037.73-.69 1.096-1.522 1.096-2.492zM6.505 32.377c-.486-.488-.73-1.056-.73-1.705V7.958c0-.649.244-1.217.73-1.704.487-.487 1.055-.73 1.704-.73h22.714c.65 0 1.217.243 1.704.73.487.487.73 1.055.73 1.704v22.714c0 .65-.243 1.217-.73 1.704-.487.486-1.055.73-1.704.73H8.21c-.649 0-1.217-.244-1.704-.73zm5.13 4.154h25.147V11.383h2.434v25.148c0 .65-.243 1.217-.73 1.703-.487.487-1.055.731-1.704.731H11.634z" />
                    </g>
                  </g>
                </svg>
                          </span>
            <div class="wrap">
              <span class="txt">EMAIL ALERTS</span>
              <span class="arrow">
                <svg xmlns="http://www.w3.org/2000/svg" width="29" height="15" viewBox="0 0 29 15">
                  <g>
                    <g><path fill="#d75332" d="M7 7.492h15.844" /></g>
                    <g><path fill="none" stroke="#d75332" stroke-miterlimit="20" stroke-width="1.4" d="M7 7.492h14.325" /></g>
                    <g><path fill="#d75332" d="M16.686 13.218l-.955-1.025 5.057-4.7-5.057-4.7.955-1.025 6.157 5.725z" /></g>
                  </g>
                </svg>
              </span>
            </div>
          </a>
                  </div>
              <div class="col">
                    <a href="" class="print-page quick-link">            <span class="icon">
                              <svg xmlns="http://www.w3.org/2000/svg" width="37" height="33" viewBox="0 0 37 33">
                  <g>
                    <g>
                      <path fill="#fff" d="M26.526 3.08H10.482v5.95H7.778V.377H29.23V9.03h-2.704zm3.65 12.936c-.36 0-.676-.136-.946-.406a1.298 1.298 0 0 1-.406-.946 1.3 1.3 0 0 1 .406-.947c.27-.27.586-.405.946-.405.361 0 .677.135.947.405a1.3 1.3 0 0 1 .406.947c0 .36-.136.676-.406.946-.27.27-.586.406-.947.406zm-3.65 5.453H10.482v8.653h16.044zm2.704 11.357H7.778v-7.932h-7.3V13.807c0-1.353.457-2.488 1.373-3.403.917-.916 2.051-1.374 3.403-1.374h26.5c1.353 0 2.488.458 3.404 1.374.915.915 1.373 2.05 1.373 3.403v11.087h-7.3zm4.597-10.636v-8.392c0-.595-.199-1.087-.596-1.478-.397-.391-.89-.586-1.477-.586h-26.5c-.588 0-1.08.199-1.477.596-.398.398-.596.89-.596 1.477v8.383h4.597v-3.425H29.23v3.425z" />
                    </g>
                  </g>
                </svg>
                          </span>
            <div class="wrap">
              <span class="txt">PRINT PAGE</span>
              <span class="arrow">
                <svg xmlns="http://www.w3.org/2000/svg" width="29" height="15" viewBox="0 0 29 15">
                  <g>
                    <g><path fill="#d75332" d="M7 7.492h15.844" /></g>
                    <g><path fill="none" stroke="#d75332" stroke-miterlimit="20" stroke-width="1.4" d="M7 7.492h14.325" /></g>
                    <g><path fill="#d75332" d="M16.686 13.218l-.955-1.025 5.057-4.7-5.057-4.7.955-1.025 6.157 5.725z" /></g>
                  </g>
                </svg>
              </span>
            </div>
          </a>
                  </div>
        


    
                </div>
            </section>
            
        </main>
    </div>
    <footer class="footer">
        <div class="container">
        					

                        
    <h2 class="visually-hidden" id="block-footerlegal-menu">Footer Legal</h2>
    

                              <ul class="footer-menu">
                  <li>
          <a href="https://www.intelliatx.com/cookie-policy/">Cookie Policy</a>
                  </li>
              <li>
          <a href="https://www.intelliatx.com/terms-and-conditions/">Terms of Use</a>
                  </li>
              <li>
          <a href="https://www.intelliatx.com/privacy-policy/">Privacy Policy</a>
                  </li>
          </ul>
  


    
			            <div class="text-area">
                <span class="copy">&copy; 2025. Intellia Therapeutics, Inc. </span>
                					<div id="block-gbfootertext" class="block-content--nir-global-block block-content--nir-global-block--11071 block--block-content41fbef4b-6d4d-49d2-84a6-cc80948e4245 block--block-content41fbef4b-6d4d-49d2-84a6-cc80948e4245--5816 block--footer-text--block-content--41fbef4b-6d4d-49d2-84a6-cc80948e4245 block--footer-text--block-content--41fbef4b-6d4d-49d2-84a6-cc80948e4245--5816 block--f341fb68-8ff4-4dd0-99f1-d80acdc999c3 block--f341fb68-8ff4-4dd0-99f1-d80acdc999c3--5816 block block-block-content block-block-content41fbef4b-6d4d-49d2-84a6-cc80948e4245">
  
    
      
            <div class="field field--name-field-nir-global-block-node field--type-entity-reference field--label-hidden field__item">  
            <div class="field field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item"><p><em>Intellia Therapeutics and the Intellia Therapeutics logo are registred trademarks with the U.S. Patent &amp; Trademark Offce.</em></p></div>
      
</div>
      
  </div>

				            </div>
        </div>
    </footer>
</div>

  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb88161\/themes\/site\/client_site_202","currentQuery":{"page":"6"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNUdFuxCAM-6GqTPdDUYBcl2uAKUl3178fpQ_bTds0ISHbOEaYJEzVwdgJLi-X0N5J79qZTZUVIhqFA3Bq9ZvkrUlEHWJaKbM3hYzeVxSy8AmHpaCu5MMAUVpaA1aU3RwUnevSg3vOK6r_y24wsn_xFsIKSqmVQrXr3Oqf2T-q85XFSa9Nyzm2iXPpD8XwTMfpGy5nLweY8YYPwJwhCZoBCqmfPdw5L-QWvuAZUyIzjizsOxwX9i1tNilmfoDg3rY-8sQm62VQCcd_fACn_bR2","theme":"client_site_202","theme_token":null},"ajaxTrustedUrl":{"form_action_p_pvdeGsVG5zNF_XLGPTvYSKCf43t8qZYSwcfZl2uzM":true},"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"accessible_accordions":true,"chairtextvars":{"chairpersontext":"Committee Chair","chairtext":"Chair"},"lfg_accordions":{"no_functionality":1,"speed":"fast","show_text":"Show All","hide_text":"Hide All","show_all":0},"lfg_chosen":{"enabled":1,"blank_text":"Choose from list","disable_search":1,"disable_search_threshold":10},"user":{"uid":0,"permissionsHash":"a51693cf3270ab3357f528dd962beda5ec43cd6017a68ea03c2d52d59f71c17c"}}</script>
<script src="https://code.jquery.com/jquery-3.6.3.min.js" data-cookieconsent="ignore"></script>
<script src="/sites/g/files/knoqqb88161/files/js/js_J6JZF9f6ci15hSKKyz-jH2BxDi_4SHbGEk-tn6OiZ-w.js?scope=footer&amp;delta=1&amp;language=en&amp;theme=client_site_202&amp;include=eJxtjYEKwlAIRX9o7MV-SJzPDZvbC3Wt_r63VVQQgtwr514XMaCJs0QxyBh1emVPH9ksFZlXDZkrhunXNqTCS4BLMHSnLpUr22bVvYJoE8fRDL0WmtLfazuIBttQbD5im-SRw9OXbpGI3aUXlbjDjtZF6_PPBUdOb9HiGW-AOQMpugMqW_gD7fBdMg" data-cookieconsent="ignore"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1" data-cookieconsent="ignore"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9" data-cookieconsent="ignore"></script>
<script src="/sites/g/files/knoqqb88161/files/js/js_BD4Sy9e4KCQAdjxb3_NSd-xd-HPpcQoSGz9zECeYuBk.js?scope=footer&amp;delta=4&amp;language=en&amp;theme=client_site_202&amp;include=eJxtjYEKwlAIRX9o7MV-SJzPDZvbC3Wt_r63VVQQgtwr514XMaCJs0QxyBh1emVPH9ksFZlXDZkrhunXNqTCS4BLMHSnLpUr22bVvYJoE8fRDL0WmtLfazuIBttQbD5im-SRw9OXbpGI3aUXlbjDjtZF6_PPBUdOb9HiGW-AOQMpugMqW_gD7fBdMg" data-cookieconsent="ignore"></script>

    <style type="text/css">
body .uwy .uai:focus-within {
	box-shadow: 0 0 0 4px rgba(0,0,0,.22) !important;
	outline: 2px solid #000 !important;
	outline-offset: -2px !important;
}
</style>
  </body>
</html>
